

LETTERS TO THE EDITOR

Expanding the organ donor pool: The Spanish Model

To the Editor: We read with interest the discussions of Dr. Hou regarding the best ways to improve organ donations [1]. As usually happens in this field, most strategies are cited to imply that they did not achieve significant improvements. Rather surprising, the Spanish experience is not even considered, despite the fact that Spain is the only large country (40 million citizens) in the world with a sustained and progressive increase of cadaveric organ donation rates during the last decade.

Since the National Transplant Organization was established in 1989, together with a national network of in-hospital, specifically trained, part-time, dedicated, and strongly motivated physicians in charge of organ procurement [2], Spain has increased its organ donations from 14 to 33.6 organ donors per million people in 1999, a 142% increase [3]. This organ donor rate is by far the highest in the world (the United States has 21.8 per million people, Canada has 13.8, and the mean of the other European countries is 14.3), which has also resulted in the highest transplant rates of cadaveric kidney, liver, heart, and lungs [4]. There was no change in legislation during this period and, as in most European countries, permission from the family is always obtained before donation.

The number of renal transplants rose from 1039 in 1989 to 2023 ten years later, 99% cadaveric (50.6 per million people versus 29.9 in the United States), a significant and sustained increase that, at least in our opinion, deserves a reference in reviews from authors of possible methods to expand the donor pool. The “Spanish Model” results from the efforts of many to overcome obstacles such as untrained or under trained staff, unidentified donors, and the reluctance to approach grieving family members.

RAFAEL MATESANZ and BLANCA MIRANDA
Madrid, Spain

Correspondence to Rafael Matesanz, M.D., Nephrology Service, Hospital Ramon y Cajal, Ctra de Colmenar Km 9, 100, 28034, Madrid, Spain.
E-mail: rafmatesanz@yahoo.es

REFERENCES

1. Hou S: Expanding the donor pool: Ethical and medical considerations. *Kidney Int* 58:1820–1836, 2000

2. MATESANZ R, MIRANDA B, FELIPE C: Organ procurement in Spain: The impact of transplant coordination. *Clin Transplant* 8:281–286, 1994
3. MATESANZ R, MIRANDA B, FELIPE C, NAYA T: Continuous improvement in organ donation. *Transplantation* 61:1119–1121, 1996
4. International figures on organ donation and transplantation—1999, in *Transplant Newsletter*, Council of Europe 5:18–19, 2000

Bone mass evolution after renal transplantation

To the Editor: Now that tailoring immunosuppression is possible, efforts have concentrated on the prevention of post-transplant complications, including bone demineralization. In this context, the recent study by Westeel et al suggests that cyclosporine-steroid immunosuppression may prevent post-transplant osteopenia [1].

Unfortunately, this conclusion is not convincing. It rests only upon data collected between 3 and 24 months post-transplantation. When the first post-transplant months are included, all published studies agree that cyclosporine-steroid-based immunosuppression is consistently associated with bone loss [2, 3]. We have confirmed this conclusion in 44 unselected graft recipients (Fig. 1).

The bone loss between 3 and 24 months post-transplantation that can be anticipated from the results of previous studies averages 1.5% [2, 3]. The results of Westeel et al that were collected during this interval are thus of borderline significance when the precision error of the methods used to evaluate bone mass is considered (0.4 and ± 2 to 4% for the dual energy x-ray absorptiometry and the quantitative computed tomography [4], respectively).

Finally, these authors' conclusions are limited by patient selection, specifically excluding osteopenic post-menopausal women. Indeed, the independent effect on bone mass when the normal ovarian cycle is resumed in pre-menopausal women, as well as the prescription of potential osteogenic drugs (such as statins or thiazides) and the increased mobilization associated with successful renal transplantation, is not considered.

The clinician concerned with the fate of the patient throughout the first post-transplant year will find minimal data to rely on cyclosporine to specifically protect bone structure.

E. GOFFIN, J. P. DEVOGELAER, G. DEPRESSEUX,
and C. VAN YPERSELE DE STRIHOU
Brussels, Belgium




Fig. 1. Bone mineral density measured by dual energy x-ray absorptiometry at 12 months post-transplantation. It is expressed as the percentage of the value obtained at the time of transplantation. It falls significantly in all the evaluated sites. Immunosuppression includes cyclosporine, steroids (maintenance dose of 7.5 mg/day after 120 days) and either mycophenolate mofetil or azathioprine. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).

Correspondence to E. Goffin, Department of Nephrology, Université Catholique de Louvain, Hôpital St Luc, Av Hippocrate 10, 1200 Brussels, Belgium.
E-mail: goffin@nefr.ucl.ac.be

REFERENCES

1. WESTEEL FP, MAZOUZ H, EZAITOUNI F, *et al*: Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. *Kidney Int* 58:1788–1796, 2000
2. JULIAN BA, LASKOW DA, DUBOVSKY J, *et al*: Rapid loss of vertebral mineral density after renal transplantation. *N Engl J Med* 325:544–550, 1991
3. ALMOND MK, KWAN JTC, EVANS K, CUNNINGHAM J: Loss of regional bone mineral density in the first 12 months following renal transplantation. *Nephron* 66:52–57, 1994
4. BLAKE GM, WAHNER HW, FOGELMAN I: Technical principles of x-ray absorptiometry, in *The Evaluation of Osteoporosis: Dual Energy X-ray Absorptiometry and Ultrasound in Clinical Practice* (2nd ed), edited by BLAKE GM, WAHNER HW, FOGELMAN I, London, Martin Dunitz Ltd., 1999, pp 45–72

Selectivity of proteinuria can be estimated reliably from samples of second-morning urine

To the Editor: In a recent issue of *Kidney International*, Bazzi *et al* showed that the ratio of IgG and transferrin clearances, the selectivity index, provides valuable information in the management of the renal patient [1]. It requires, however, the measurement of transferrin and IgG in serum as well as in urine.

This is in contrast to the convenient concept of measur-

Table 1. Glomerular selectivity by urinary Ig/transferrin ratio vs. selectivity index

SI index	Ig/transferrin urine ratio (N)		
	Selective (<0.67)	Moderately selective (0.67–1.0)	Unselective (>1.0)
0.0–0.1	2		
0.1–0.2	5	4	
0.2–0.3	1	7	5
0.3–0.4			14
Unselective		4	125

ing all urinary parameters from a single sample of second morning urine, collected 2 hours after the first urination. With creatinine adjustment, the measured protein concentrations are comparable to those yielded by 24-hour urine collections. Postrenal proteinuria can be excluded by measuring α_2 -macroglobulin [3].

Selectivity can then be calculated solely by the ratio of IgG to transferrin in urine. This ratio compares well with the laborious selectivity index. In 167 samples, we compared the selectivity index with the urinary IgG/transferrin ratio and found a high degree of correspondence (Table 1). Of the samples, 97% (125 of 129) were correctly classified as unselective by measuring only the transferrin/IgG ratio in urine. There was some overlap between selective and unselective patterns when the selectivity index was between 0.2 and 0.3, while samples with a selectivity index of less than 0.2 always presented with a selective pattern.

The selectivity index, however, will provide more accurate results in the presence of prerenal or postrenal protein variabilities. IgG, for instance, can be elevated in serum because of monoclonal or polyclonal components, while a postrenal IgG increase may accompany a urinary tract infection.